GlassScriptPhysician profile
Anita Ramirez
NPI 1871134502
$4,892.37
in general payments reported to CMS, 2019-2025
30 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $877 · 2023: $1,265 · 2024: $1,239 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,015.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,188.37 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $972.03 | 2022-2025 | Farxiga, Airsupra, Andexxa |
| Lilly USA, LLC | $571.95 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $302.33 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $204.86 | 2022-2025 | |
| Currax Pharmaceuticals LLC | $200.25 | 2022-2025 | Contrave, Onzetra Xsail, Nexletol |
| Amgen INC. | $174.25 | 2022-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.14 | 2022-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $104.86 | 2022-2025 | Wegovy |
| Azurity Pharmaceuticals, INC. | $99.37 | 2023-2025 | Horizant, Edarbi |
| Exact Sciences Corporation | $88.77 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $88.56 | 2023-2025 | Trintellix |
| Intra-Sana Laboratories | $86.51 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Sumitomo Pharma America, INC. | $86.33 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.17 | 2022-2024 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $77.41 | 2022-2024 | Livalo, Seglentis |
| Astellas Pharma US INC | $70.24 | 2024-2025 | Veozah |
| Dexcom, INC. | $69.17 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $48.17 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Edwards Lifesciences Corporation | $47.88 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $42.07 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $30.98 | 2022-2025 | Capvaxive |
| Axsome Therapeutics, INC. | $23.17 | 2025 | Symbravo |
| Cormedix INC. | $22.80 | 2025 | Defencath |
| Eisai INC. | $19.72 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.88 | 2025 | Caplyta |
| Amarin Pharma, INC. | $16.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.43 | 2022 | |
| Corium, LLC | $12.56 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.